Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong
First Half Of 2022 Venture Cash Equals 2019 Full-Year Total
Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.
